DK2825175T3 - Rho-kinase-inhibitorer til anvendelse i behandling af amyotrofisk lateral sklerose - Google Patents
Rho-kinase-inhibitorer til anvendelse i behandling af amyotrofisk lateral skleroseInfo
- Publication number
- DK2825175T3 DK2825175T3 DK13708430.7T DK13708430T DK2825175T3 DK 2825175 T3 DK2825175 T3 DK 2825175T3 DK 13708430 T DK13708430 T DK 13708430T DK 2825175 T3 DK2825175 T3 DK 2825175T3
- Authority
- DK
- Denmark
- Prior art keywords
- rho
- treatment
- kinase inhibitors
- lateral sclerosis
- amyotrophic lateral
- Prior art date
Links
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 title 1
- 239000003590 rho kinase inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261609576P | 2012-03-12 | 2012-03-12 | |
| PCT/EP2013/054804 WO2013135596A1 (en) | 2012-03-12 | 2013-03-11 | Rho kinase inhibitors for use in treating amyotrophic lateral sclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2825175T3 true DK2825175T3 (da) | 2017-11-06 |
Family
ID=47844328
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK13708430.7T DK2825175T3 (da) | 2012-03-12 | 2013-03-11 | Rho-kinase-inhibitorer til anvendelse i behandling af amyotrofisk lateral sklerose |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US9980972B2 (da) |
| EP (1) | EP2825175B1 (da) |
| DK (1) | DK2825175T3 (da) |
| ES (1) | ES2644238T3 (da) |
| WO (1) | WO2013135596A1 (da) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018226603A1 (en) * | 2017-06-04 | 2018-12-13 | Dun Yang | Process for exploiting synthetic lethality based on overexpression of myc oncogene |
| CA3162382A1 (en) | 2020-01-09 | 2021-07-15 | Thomas Macallister | Methods of treating cortical dementia associated wandering |
| WO2021162808A1 (en) * | 2020-02-10 | 2021-08-19 | Woolsey Pharmaceuticals, Inc | Methods of treating pseudobulbar affect and other emotional disturbances |
| MX2022011519A (es) * | 2020-03-25 | 2022-10-07 | Woolsey Pharmaceuticals Inc | Metodos de uso de inhibidores de la quinasa rho para tratar demencia frontotemporal. |
| US11642352B2 (en) | 2020-03-25 | 2023-05-09 | Woolsey Pharmaceuticals, Inc. | Methods of treating wandering in Lewy dody dementia |
| CN115996728A (zh) | 2020-04-23 | 2023-04-21 | 乌尔塞制药公司 | 利用Rho激酶抑制剂治疗阿尔茨海默病的方法 |
| US20240299408A1 (en) | 2020-10-22 | 2024-09-12 | Woolsey Pharmaceuticals, Inc. | Methods of treating 4-repeat tauopathies |
| US11779588B2 (en) | 2021-10-15 | 2023-10-10 | Woolsey Pharmaceuticals, Inc. | Method of treating amyotrophic lateral sclerosis |
| EP4415716A4 (en) * | 2021-10-15 | 2025-07-09 | Woolsey Pharmaceuticals Inc | METHOD FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS |
| JP2024543347A (ja) * | 2021-11-12 | 2024-11-21 | ウールジー・ファーマシューティカルズ・インコーポレイテッド | 筋萎縮性側索硬化症を治療する方法およびそれに対する投与計画 |
| US20240423998A1 (en) | 2021-11-29 | 2024-12-26 | Woolsey Pharmaceuticals, Inc. | Methods of treating agitation and other dementia-associated behavioral symptoms |
| US12128053B2 (en) * | 2022-02-17 | 2024-10-29 | Woolsey Pharmaceuticals, Inc | Taste-masking oral formulations of fasudil |
| MX2024010030A (es) | 2022-02-17 | 2024-09-24 | Woolsey Pharmaceuticals Inc | Formulaciones orales de fasudil con resina de intercambio ionico. |
| EP4551227A1 (en) * | 2022-07-08 | 2025-05-14 | Woolsey Pharmaceuticals, Inc. | Treating amyotrophic lateral sclerosis having onset 24 months prior to treatment |
| US20250381197A1 (en) * | 2022-07-08 | 2025-12-18 | Woolsey Pharmaceuticals, Inc. | Regimen for Treating Amyotrophic Lateral Sclerosis Having Onset 24 Months Prior to Treatment |
| WO2024061474A1 (en) * | 2022-09-23 | 2024-03-28 | Norwegian University Of Science And Technology (Ntnu) | Combination therapy for the treatment or prevention of neurological disorders |
| EP4601636A1 (en) * | 2022-10-14 | 2025-08-20 | Woolsey Pharmaceuticals, Inc. | Method of treating amyotrophic lateral sclerosis by oral administration of fasudil |
| WO2025160116A1 (en) * | 2024-01-23 | 2025-07-31 | Woolsey Pharmaceuticals, Inc. | Methods of treating amyotrophic lateral sclerosis by oral administration of fasudil |
| WO2025207476A1 (en) * | 2024-03-25 | 2025-10-02 | Woolsey Pharmaceuticals, Inc. | Methods for treating als with a rho kinase inhibitor based on use of neurofilament light chain biomarker |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4678783B1 (en) | 1983-11-04 | 1995-04-04 | Asahi Chemical Ind | Substituted isoquinolinesulfonyl compounds |
| CN1080721C (zh) | 1995-07-03 | 2002-03-13 | 旭化成株式会社 | 1－(5－异喹啉磺酰基)高哌嗪盐酸盐水合物 |
| EP1110553B1 (en) | 1998-08-10 | 2013-03-27 | Asahi Kasei Pharma Corporation | Sustained release oral preparations of fasudil hydrochloride |
| DE10153605A1 (de) * | 2001-11-02 | 2003-05-28 | Morphochem Ag Komb Chemie | Verwendung von Inhibitoren der Rho-Kinasen zur Stimulation des Nervenwachstums, zur Inhibition der Narbengewebsbildung und/oder Reduktion eines Sekundärschadens |
| WO2005117896A1 (de) | 2004-06-03 | 2005-12-15 | Schering Aktiengesellschaft | Formulierungen, die fasudil, eine matrix und einem mantel enthalten |
| JP2007246466A (ja) * | 2006-03-17 | 2007-09-27 | Osaka Univ | 中枢神経損傷に対する嗅粘膜移植にＲｈｏキナーゼ阻害剤を用いた神経機能再建法 |
| JP2009292782A (ja) | 2008-06-06 | 2009-12-17 | Asahi Kasei Pharma Kk | 神経新生及び／又は神経再生促進剤 |
| CN101612157A (zh) * | 2008-06-26 | 2009-12-30 | 天津红日药业股份有限公司 | 法舒地尔诱导成年脑内源性神经干细胞再生的用途 |
| US20120010196A1 (en) * | 2010-04-02 | 2012-01-12 | Qin Quingyu | Methods of treating neurodegenerative disorders and diseases |
-
2013
- 2013-03-11 EP EP13708430.7A patent/EP2825175B1/en active Active
- 2013-03-11 ES ES13708430.7T patent/ES2644238T3/es active Active
- 2013-03-11 US US14/384,549 patent/US9980972B2/en active Active
- 2013-03-11 DK DK13708430.7T patent/DK2825175T3/da active
- 2013-03-11 WO PCT/EP2013/054804 patent/WO2013135596A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| US20150031683A1 (en) | 2015-01-29 |
| EP2825175B1 (en) | 2017-07-26 |
| WO2013135596A1 (en) | 2013-09-19 |
| US9980972B2 (en) | 2018-05-29 |
| EP2825175A1 (en) | 2015-01-21 |
| ES2644238T3 (es) | 2017-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2825175T3 (da) | Rho-kinase-inhibitorer til anvendelse i behandling af amyotrofisk lateral sklerose | |
| CY2022018I1 (el) | Κρυσταλλικες μορφες αναστολεα προλυλο υδροξυλασης | |
| SMT201700111B (it) | Eterociclilammine come inibitori di pi3k | |
| SMT201700052B (it) | 2-(azaindol-2-il)benzimidazoli come inibitori di pad4 | |
| SMT201700109B (it) | Inibitori di istone demetilasi | |
| EP2683693A4 (en) | ROR-GAMMA-T INHIBITORS | |
| DK2844256T3 (da) | Behandling af amyotrofisk lateral sklerose med tyrosinkinase-inhibitorer | |
| DK2857401T3 (da) | Hidtil ukendt -lactamaseinhibitor og fremgangsmåde til at fremstille samme | |
| KR102096014B9 (ko) | PCSK9 iRNA 조성물 및 그 사용 방법 | |
| HRP20182037T1 (hr) | Inhibitori prmt5 i njihova uporaba | |
| DK2804858T3 (da) | Metalloenzym-inhibitorforbindelser | |
| DK2928477T3 (da) | Anvendelse af telomeraseinhibitor imetelstat til behandling af myelofibrosis | |
| HUE051648T2 (hu) | CCR3-gátlók használata | |
| DK2906580T3 (da) | Behandling af amyotrofisk lateral sklerose | |
| HRP20182043T8 (hr) | Upotreba anti-koneksinskih sredstava za poboljšanje terapijskog učinka inhibitora acetilkolinesteraze | |
| EP2921510A4 (en) | SURFACE TREATMENT COMPOSITION | |
| DK2500036T3 (da) | MET-hæmmere til øgning af virkningen af radioterapi | |
| DK2888010T3 (da) | Fremgangsmåder til at hæmme fascin | |
| EP3632467C0 (en) | COMPLEMENT FACTOR H INHIBITORS | |
| EP2858975A4 (en) | FBXO3 INHIBITORS | |
| DK2928835T3 (da) | Anvendelse af aktivt kul i membranbioreaktor | |
| PL2854792T3 (pl) | Kompozycja do zapobiegania bólom głowy | |
| DK2888228T3 (da) | Inhibitorer af CD40-TRAF6 interaktion | |
| EP2914249A4 (en) | TRANSDERMAL PROPYNYLAMINOINDANE COMPOSITIONS | |
| HUE060237T2 (hu) | Szedoheptulóz alkalmazása gyulladás megelõzésére vagy kezelésére |